PEDRO TROYA, M.D.
Endocrinology, Diabetes & Metabolism Physician in TAMPA, Florida. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.
What the federal data shows
PEDRO TROYA, M.D. reported a CMS MIPS final score of 75/100 — below the 83.1 national average — and filed 3,345 Medicare Part D claims in 2023.
- 75/100
- MIPS score · -8 vs avg
- 3K
- Part D claims, 2023
- 39%
- generic prescribing
- Likely
- board-certified (heuristic)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.
PEDRO TROYA, M.D.'s MIPS score vs every scored U.S. clinician
CMS Merit-based Incentive Payment System (MIPS) final score, 2023 — the federal quality measure
75 15th percentile higher than 15% of 477,587 scored providers
Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Merit-based Incentive Payment System (MIPS) · 2023
PEDRO TROYA, M.D. practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting + 1 hospital affiliation — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about PEDRO TROYA, M.D.?
Below national averagePrimary specialty
Medicare Part D claims
MIPS final score
Specialty distribution in Florida
How Endocrinology, Diabetes & Metabolism Physician compares to other specialties among Florida providers
Endocrinology, Diabetes & Metabolism Physician share within Florida
Endocrinology, Diabetes & Metabolism Physician is one of the more visible NUCC categories in Florida
Each bar reflects the share of in-state providers whose primary NUCC taxonomy matches the specialty. Long tail of ~690 NUCC codes folded into "Other" to keep the comparison legible.
Medicare quality performance — MIPS
PEDRO TROYA, M.D.'s 2023 MIPS final score plotted against the Endocrinology, Diabetes & Metabolism Physician national average
- MIPS Final Score
- 75/100
- vs 83.1 national avg · 2023 performance year
MIPS final score (Endocrinology, Diabetes & Metabolism Physician) — 75/100 vs national avg 83.1
Quality benchmarks
- National MIPS avg 2023 reporting year
- Specialty volume Endocrinology, Diabetes & Metabolism Physician US NPIs
75/100 MIPS final score — 8.1 pts below the 83.1 national average
Quality, Cost, Promoting Interoperability, and Improvement Activities composite score for the 2023 performance year. Specialty: Endocrinology, Diabetes & Metabolism Physician.
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
PEDRO TROYA, M.D. appears in the CMS NPPES registry as a Endocrinology, Diabetes & Metabolism Physician provider holding M.D. credentials at 4816 N ARMENIA AVE, TAMPA, FL, 33603, with a listed phone of (813) 876-3636. NPI 1427187319 was issued on 03/05/2007. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what TROYA most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.
Medicare Part D records for calendar year 2023 show 3,345 prescription claims written by this provider, covering 505 Medicare beneficiaries and totaling roughly $2.2 million in drug spend, split 61% brand-name and 39% generic by claim count. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 75/100 for the 2023 performance year, compared with the national average of 83.1.
Endocrinology, Diabetes & Metabolism Physician is a mid-sized specialty nationwide, with 7,852 enrolled providers across 54 states and an average of 2,639 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1427187319 |
|---|---|
| Specialty | Endocrinology, Diabetes & Metabolism Physician |
| Credentials | M.D. |
| Gender | Male |
| NPI Issued | 03/05/2007 |
Verify this provider's license
PlainDoctor pulls this profile from the CMS NPPES public registry. Confirm PEDRO TROYA, M.D.'s current license status, disciplinary history, and board certifications with the Florida Board of Medicine in Florida before relying on this page for a clinical or care decision.
How we sourced this profile
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
Reporting: Individual
Hospital and facility affiliations
Facilities where PEDRO TROYA, M.D. bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" — a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.
Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).
Industry payments received (2024) — CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for PEDRO TROYA, M.D.. Source: openpaymentsdata.cms.gov.
Total received
$1.9K
Largest payer
Novo Nordisk Inc
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
License & disciplinary context — Florida FLDOH 2023 annual report
Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~75K Florida medical licensees in 2023 — they are NOT specific to PEDRO TROYA, M.D.. To verify PEDRO TROYA, M.D.'s current license status, search the FLDOH public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
FLDOH publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the Florida disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Brand-heavy
61% brand-name claims vs 39% generic, on 3,345 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
Prescribing Breakdown
- 30-Day Fills
- 8,252
- Total Day Supply
- 244,400
- Brand vs Generic
- 61% brand / 39% generic
- Brand Drug Cost
- $2.1M
- Generic Drug Cost
- $33K
Patient Demographics
- Average Patient Age
- 71.5 years
- Avg HCC Risk Score
- 1.81
- Gender Split
- 60% female / 40% male
- Age Distribution
- <65: 67, 65-74: 254, 75-84: 154, 85+: 30
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What PEDRO TROYA, M.D. prescribes most
Top Medicare Part D drugs by claim count, 2023
- Levothyroxine Sodium
Levothyroxine Sodium
411 claims
- Ozempic
Ozempic
248 claims
- Metformin Hcl
Metformin Hcl
192 claims
- Synthroid 145
Synthroid
145 claims
- Jardiance 142
Jardiance
142 claims
- Metformin Hcl Er 87
Metformin Hcl Er
87 claims
- Methimazole 85
Methimazole
85 claims
- Novolog Flexpen 85
Novolog Flexpen
85 claims
| Drug | Claims |
|---|---|
| Levothyroxine Sodium | 411 |
| Ozempic Semaglutide | 248 |
| Metformin Hcl | 192 |
| Synthroid Levothyroxine Sodium | 145 |
| Jardiance Empagliflozin | 142 |
| Metformin Hcl Er Metformin Hcl | 87 |
| Methimazole | 85 |
| Novolog Flexpen Insulin Aspart | 85 |
| Tresiba Flextouch U-100 Insulin Degludec | 79 |
| Humalog Kwikpen U-100 Insulin Lispro | 76 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Endocrinology, Diabetes & Metabolism Physician Overview
How PEDRO TROYA, M.D. fits within the Endocrinology, Diabetes & Metabolism Physician landscape nationally.
PEDRO TROYA, M.D.'s 3,345 claims are above the specialty average of 2,639.
Nearby Endocrinology, Diabetes & Metabolism Physician Providers in Florida
Other clinicians with the same primary specialty enrolled in Florida, drawn from the same CMS NPPES roster as TROYA.
Compare Endocrinology, Diabetes & Metabolism Physician nationally: see state-by-state distribution →
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
Explore Florida
Frequently Asked Questions
What is PEDRO TROYA, M.D.'s specialty? ▼
How much does PEDRO TROYA, M.D. prescribe under Medicare Part D? ▼
What is PEDRO TROYA, M.D.'s Medicare quality score? ▼
Where is PEDRO TROYA, M.D. located? ▼
What is PEDRO TROYA, M.D.'s NPI number? ▼
Does PEDRO TROYA, M.D. prescribe more brand-name or generic drugs? ▼
How many Endocrinology, Diabetes & Metabolism Physician providers are there in the US? ▼
What drugs does PEDRO TROYA, M.D. prescribe most often? ▼
Does PEDRO TROYA, M.D. accept Medicare? ▼
How can I verify PEDRO TROYA, M.D.'s credentials? ▼
Data Sources
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology